Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats unresectable or metastatic esophageal squamous cell carcinoma (ESCC). Sold as Tevimbra. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Tislelizumab-Jsgr (sold as Tevimbra), first approved Mar 13, 2024, with 10 new uses approved and 0 published complete response letters.
First approved: Mar 13, 2024
Applications: 2
New uses approved: 10
Complete response letters: 0
Medicare spending, 2025: $4.9M
Orphan exclusivity until: Mar 3, 2032
First approved in the EU: Sep 15, 2023
First approved in Japan: Mar 27, 2025
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 12 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Tevimbra, new ingredientA drug with a new active ingredient indicated for the treatment of unresectable advanced or recurrent esophageal cancer. · BeiGene Japan GK · Mar 27, 2025
Clinical Trials
2 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
